GoAI
Get started
Evommune, Inc. logo

Evommune, Inc.

EVMN

NYSEHealthcareBiotechnology

Open in GoAI

Previous close

$14.02

+$0.45 · +3.32%

Aug 21, 4:00 PM ET

EVMN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

73

Undervalued

Momentum

21

Weakening

Sentiment

56

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Luis C. Pena
Listed since
Nov 6, 2025
Employees
48

Market position

Day range

Current $14.02

52-week range

Current $14.02

Open
$13.74
Previous close
$13.57
Volume
275.08K
0.42× average
Average volume
661.76K
Average daily volume
Market cap
508.82M USD
Beta
0.96
Market reference 1
50-day average
$14.8968
-5.89% below average
200-day average
$20.2361
-30.72% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
497.69M USD
EV / EBITDA
-7.38×
Earnings yield
-12.76%
Free cash flow yield
-14.21%

Profitability & efficiency

Return on equity
-33.50%
Return on assets
-30.62%
Return on invested capital
-39.05%

Financial health

Current ratio
8.57×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends210%-230%-670%-1110%Gross margin, FY2023: 80.00%Gross margin, FY2024: 81.61%Gross margin, FY2025: 100.00%Operating margin, FY2023: -757.00%Operating margin, FY2024: -1000.19%Operating margin, FY2025: -623.62%Net margin, FY2023: -681.06%Net margin, FY2024: -954.40%Net margin, FY2025: -529.77%FY2023FY2024FY2025
Gross margin FY2023 80.00%. Gross margin FY2024 81.61%. Gross margin FY2025 100.00%. Operating margin FY2023 -757.00%. Operating margin FY2024 -1000.19%. Operating margin FY2025 -623.62%. Net margin FY2023 -681.06%. Net margin FY2024 -954.40%. Net margin FY2025 -529.77%.

Income trends

Revenue

13M USD+85.71%

Operating income

−81.07M USD-15.79%

Net income

−68.87M USD-3.09%
Income trends across reported periods22.41M USD−15.22M USD−52.85M USD−90.48M USDRevenue, FY2023: 5M USDRevenue, FY2024: 7M USDRevenue, FY2025: 13M USDOperating income, FY2023: −37.85M USDOperating income, FY2024: −70.01M USDOperating income, FY2025: −81.07M USDNet income, FY2023: −34.05M USDNet income, FY2024: −66.81M USDNet income, FY2025: −68.87M USDFY2023FY2024FY2025
Revenue FY2023 5M USD. Revenue FY2024 7M USD. Revenue FY2025 13M USD. Operating income FY2023 −37.85M USD. Operating income FY2024 −70.01M USD. Operating income FY2025 −81.07M USD. Net income FY2023 −34.05M USD. Net income FY2024 −66.81M USD. Net income FY2025 −68.87M USD.
Metric (USD)FY2025FY2024FY2023
Revenue13M USD7M USD5M USD
Cost of goods sold—1.29M USD1M USD
Gross profit13M USD5.71M USD4M USD
Research and development74.04M USD64.24M USD32M USD
Selling, general, and administrative20.03M USD11.48M USD9.85M USD
Operating expenses94.07M USD75.73M USD41.85M USD
Interest income3.32M USD3.24M USD3.86M USD
Interest expense—34K USD58K USD
Depreciation and amortization1.39M USD1.29M USD1M USD
Operating income−81.07M USD−70.01M USD−37.85M USD
Net income−68.87M USD−66.81M USD−34.05M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
40%
2 beats, 3 misses, 0 met estimates
Average EPS surprise
-170.25%
5 comparable reports
Latest EPS result
-0.89
Estimate -0.66 · Miss by 33.94%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.38-3.15-5.91-8.68Q4 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q4 2025, reported Oct 9, 2025: actual -0.45, estimate -6.08, surprise +92.60%, Beat. Q4 2025, reported Dec 11, 2025: actual -8.07, estimate -0.842, surprise -858.43%, Miss. Q1 2026, reported Mar 5, 2026: actual -1.43, estimate -0.82, surprise -74.39%, Miss. Q2 2026, reported May 7, 2026: actual -0.64, estimate -0.83, surprise +22.89%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.89, estimate -0.664, surprise -33.94%, Miss. Q4 2026, reported Oct 16, 2026: actual —, estimate -0.82, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.76M7.32M3.87M425KQ4 '25EstimateQ4 '25BeatQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q4 2025, reported Oct 9, 2025: actual —, estimate 3.33M USD, surprise —, Comparison unavailable. Q4 2025, reported Dec 11, 2025: actual 10M USD, estimate 3.33M USD, surprise +200.00%, Beat. Q1 2026, reported Mar 5, 2026: actual —, estimate 722.17K USD, surprise —, Comparison unavailable. Q2 2026, reported May 7, 2026: actual —, estimate 722.17K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual —, estimate 1.33M USD, surprise —, Comparison unavailable. Q4 2026, reported Oct 16, 2026: actual —, estimate 500K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$38.00

171.04% upside
Past 12 months12-month forecastHigh $50.00Average $38.00Low $26.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy250%
Hold250%
Sell00%
Strong sell00%

EVMN peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding EVMN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.31M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.44M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.94M
Weight
0.03%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.62M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.42M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
804.67K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
722.33K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
600.91K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research EVMN

research.disclaimer